Maag becomes CEO at Kyverna
Plus Bernstein to head R&D at Maze, and updates from Visiox, Araris, Quest and Biohaven
Cell therapy company Kyverna Therapeutics Inc. named Peter Maag as CEO, succeeding Dominic Borie, who will become president of R&D. Maag, who also joins the board, was executive chairman, president and CEO of CareDx Inc. (NASDAQ:CDNA) and prior to that held multiple positions at Novartis AG (SIX:NOVN; NYSE:NVS), including president of diagnostics, country president for Germany and head of strategy for Novartis Pharmaceuticals.
Maze Therapeutics Inc. hired Harold Bernstein as president of R&D and CMO, and promoted Eric Green to CSO from SVP of research and translational sciences. Bernstein joins from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), where he was SVP, CMO and head of global clinical development. Maze is applying data science methods to develop therapies for genetically defined diseases. ...